These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 11838269)

  • 1. Olanzapine Modulate Lipid Metabolism and Adipose Tissue Accumulation via Hepatic Muscarinic M3 Receptor-Mediated Alk-Related Signaling.
    Su Y; Cao C; Chen S; Lian J; Han M; Liu X; Deng C
    Biomedicines; 2024 Jun; 12(7):. PubMed ID: 39061977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cevimeline (Evoxac ®) overdose.
    Voskoboynik B; Babu K; Hack JB
    J Med Toxicol; 2011 Mar; 7(1):57-9. PubMed ID: 20865466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cevimeline.
    Weber J; Keating GM
    Drugs; 2008; 68(12):1691-8. PubMed ID: 18681491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
    Arisawa H; Fukui K; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
    Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
    Arisawa H; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
    Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
    Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors.
    Iga Y; Arisawa H; Ogane N; Saito Y; Tomizuka T; Nakagawa-Yagi Y; Masunaga H; Yasuda H; Miyata N
    Jpn J Pharmacol; 1998 Nov; 78(3):373-80. PubMed ID: 9869272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
    Fox RI; Konttinen Y; Fisher A
    Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
    Shiozawa A
    Nihon Yakurigaku Zasshi; 2002 Oct; 120(4):253-8. PubMed ID: 12425151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
    Fox RI
    Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.